Related Experiment Video
Updated: Apr 11, 2026
Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
Biomarkers for pediatric pulmonary arterial hypertension: challenges and recommendations
Ozus Lohani1, Kelley L Colvin2, Michael E Yeager2
1Department of Bioengineering, University of Colorado Denver; Department of Pediatrics-Critical Care.
Insights
Pediatric pulmonary arterial hypertension (PAH) is a serious childhood condition. Identifying specific biomarkers in children with PAH is crucial for effective clinical management and improved outcomes.
Area of Science:
- Pediatric cardiology
- Pulmonology
- Biomarker research
Background:
- Pediatric pulmonary arterial hypertension (PAH) is a rare but severe condition in children.
- It leads to progressive pulmonary vascular changes and right heart failure.
- Current treatments are largely based on adult studies, highlighting a need for pediatric-specific approaches.
Purpose of the Study:
- To review the current status of biomarkers in pediatric PAH.
- To explore potential future biomarkers for this population.
- To provide recommendations for biomarker use and interpretation in pediatric PAH management.
Main Methods:
- Literature review of existing studies on pediatric PAH biomarkers.
- Analysis of current evidence-based practices derived from adult PAH studies.
- Discussion of the challenges and opportunities in pediatric biomarker research.
Main Results:
- Current biomarkers for pediatric PAH are limited and often extrapolated from adult data.
- There is a significant need for validated, pediatric-specific biomarkers.
- Biomarkers could aid in diagnosis, risk stratification, and treatment selection.
Conclusions:
- Biomarkers are essential for advancing the clinical management of pediatric PAH.
- Further research is needed to identify and validate reliable biomarkers in children.
- Standardized interpretation and application of biomarkers are key for improving patient care.
Abstract:
Pediatric pulmonary arterial hypertension (PAH) is an uncommon disease that can occur in neonates, infants, and children, and is associated with high morbidity and mortality. Despite advances in treatment strategies over the last two decades, the underlying structural and functional changes to the pulmonary arterial circulation are progressive and lead eventually to right heart failure. The management of PAH in children is complex due not only to the developmental aspects but also because most evidence-based practices derive from adult PAH studies. As such, the pediatric clinician would be greatly aided by specific characteristics (biomarkers) objectively measured in children with PAH to determine appropriate clinical management. This review highlights the current state of biomarkers in pediatric PAH and looks forward to potential biomarkers, and makes several recommendations for their use and interpretation.
More Related Videos
Related Concept Videos
01:30Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...